Santhera Pharmaceuticals

Update in progress

SANN.SW (Swiss)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company that develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need across Europe, North America, and Asia. Its lead candidate, vamorolone, is in development for Duchenne muscular dystrophy. The pipeline also includes lonodelestat for cystic fibrosis and other neutrophilic lung diseases. Founded in 2004, it is based in Pratteln, Switzerland.

Company score

Sentiment: 0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.44; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.16; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.28; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive